DiaSorin S.p.A. (DSRLF) Q4 2025 Earnings Call Transcript

Key takeaway: Immuno segment delivered 7% growth in 2025 while Molecular Diagnostics were flat year‑on‑year and LTG was flattish, with management attributing weakness in Molecular primarily to a very weak flu season and softness in Life Science. Management noted a CFO transition (current CFO Piergiorgio Pedron presenting 2025 results; Alberto Donati to discuss 2026 guidance), and will provide forward guidance separately; overall results are mixed but not materially negative.

Analysis

DiaSorin’s P&L sensitivity is driven less by headline growth and more by the mismatch between recurring consumable pull-through and lumpy instrument/LT revenue — that nonlinearity amplifies both upside on a respiratory rebound and downside from multi-quarter lab destocking. Reagent shelf-life and procurement cadence mean a single weak respiratory season can depress consumable demand for 2-4 quarters even after clinician volumes recover, creating a delayed recovery in reported Molecular revenue and margin flow-through.

Second-order winners are pure-play consumable suppliers with flexible manufacturing that can convert marginal volume into high-margin throughput quickly; losers are capital-equipment-heavy vendors whose order books are being deferred and distributors sitting on reagent inventory. Competitive dynamics favor firms that can monetize installed base service and remote reagent fulfillment (subscription or auto-replenish) — that recurring revenue both shortens cash conversion cycles and insulates against seasonal volatility.

Key catalysts to watch over the next 3-12 months: (1) any early signals of a stronger-than-expected upcoming respiratory season (w/in weeks) that would reaccelerate reagent demand, (2) quarterly inventory adjustments at large lab networks (reported as negative sales but positive leading indicator), and (3) pricing / tender actions in European public health programs which can re-rate margins quickly. Tail risk is a multi-year secular shift to point-of-care testing adoption that would structurally compress centralized lab volumes and require a material strategic pivot within 12-24 months.

Key Decisions for Investors

• Buy DSRLF (DiaSorin) equity, build a 2-3% portfolio position over 6-12 months on pullbacks >5%. Rationale: asymmetric upside if molecular consumables reaccelerate and margins recover; target +30-40% total return in 12 months, downside ~25% if weak respiratory demand persists. Use staggered entries to manage inventory/idiosyncratic risk.
• Pair trade: Long DSRLF / Short RHHBY (Roche) 12-month pair to isolate company-specific execution (use equal notional). Objective: capture 15-20% relative outperformance if DiaSorin leverages installed-base consumables while Roche trades on broader diagnostics multiple. Stop-loss: close pair if both move >15% in same direction or if macro testing demand shifts materially.
• Defined-risk options: Buy DSRLF Jan-2027 ATM calls and sell a 20-30% OTM Jan-2027 call (call spread) to cap cost. Thesis: limited premium exposure to a respiratory rebound within 6-10 months; max loss = premium paid, target 2.5-4x payoff if consumables re-accelerate.
• Short QGEN (Qiagen) or similarly exposed molecular-only names over 3-9 months as a hedge against prolonged weak seasonal respiratory volume. Rationale: names with high single-product respiratory dependence face inventory destocking and pricing pressure; risk: an abrupt viral wave would blow up the short within weeks, so size conservatively and hedge with long calls.